menu
    • menu
    [{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Intersect ENT","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Medtronic Plc","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":1.1000000000000001,"dosageForm":"Implant","sponsorNew":"Medtronic Plc \/ Medtronic Plc","highestDevelopmentStatusID":"15","companyTruncated":"Medtronic Plc \/ Medtronic Plc"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Intersect ENT","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Steroid","year":"2021","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved FDF","graph3":"Medtronic Plc","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Otolaryngology","amount2New":1.1000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Medtronic Plc \/ Medtronic Plc","highestDevelopmentStatusID":"15","companyTruncated":"Medtronic Plc \/ Medtronic Plc"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Medtronic Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Oncology","graph2":"Phase I","graph3":"Medtronic Plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medtronic Plc \/ Medtronic plc","highestDevelopmentStatusID":"6","companyTruncated":"Medtronic Plc \/ Medtronic plc"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Arecor","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Medtronic Plc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Medtronic Plc \/ Medtronic Plc","highestDevelopmentStatusID":"4","companyTruncated":"Medtronic Plc \/ Medtronic Plc"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Funding","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Medtronic Plc","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.34000000000000002,"dosageForm":"Capsule","sponsorNew":"Medtronic Plc \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Medtronic Plc \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Medtronic Plc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medtronic Plc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Medtronic Plc \/ Undisclosed"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Paracetamol","moa":"COX-1\/COX-2","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Medtronic Plc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medtronic Plc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Medtronic Plc \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Medtronic Plc

    Menu

    Medtronic Plc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abacavir

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : University of Miami

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            STARLITE for Unresectable High-Grade Gliomas

                            Details : Abacavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 24, 2024

                            Lead Product(s) : Abacavir

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : University of Miami

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Recipient : Arecor

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Arecor and Medtronic Collaborate to Develop Novel Thermostable Insulin for Pump Delivery

                            Details : The collaboration aims to develop a novel, high concentration, thermostable insulin for use by Medtronic’s Diabetes business in a next-generation implantable pump.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            May 09, 2024

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Recipient : Arecor

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Approved FDF

                            Recipient : Intersect ENT

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Medtronic Completes Acquisition of Intersect ENT

                            Details : Medtronic has acquired Intersect ENT's PROPEL™ and SINUVA™ (mometasone furoate) sinus implant product lines and technology, intellectual property, and Menlo Park, Calif., facility.

                            Product Name : Propel

                            Product Type : Steroid

                            Upfront Cash : $1,100.0 million

                            May 13, 2022

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Approved FDF

                            Recipient : Intersect ENT

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Approved FDF

                            Recipient : Intersect ENT

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Medtronic to Acquire Intersect ENT

                            Details : Intersect ENT's PROPEL® and SINUVA® sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing.

                            Product Name : Propel

                            Product Type : Steroid

                            Upfront Cash : $1,100.0 million

                            August 06, 2021

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Approved FDF

                            Recipient : Intersect ENT

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medtronic Announces FDA Approval for Minimed™ 770G Insulin Pump System with Smartphone Connectivity for Peop...

                            Details : The 770G System is a first-of-a-kind device for patients aged 2 to 6 years. It is the first legally marketed device that can automatically adjust insulin delivery based on continuous glucose monitor values for this patient population.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            September 01, 2020

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Blackstone Life Sciences

                            Deal Size : $337.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Medtronic Announces a $337 Million Product Investment from Blackstone Life Sciences to Expand Development of F...

                            Details : Funding will support Medtronic's Diabetes R&D, including a series of near-term programs such as the MiniMed™ 780G insulin pump system, its Personalized Closed Loop (PCL) system, extended wear infusion set, and Zeus and Synergy sensors.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            June 12, 2020

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Blackstone Life Sciences

                            Deal Size : $337.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of Acetaminophen on Performance of Guardianâ„¢ Sensor (3) in Adults

                            Details : Acetominophen is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 07, 2020

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin aspart

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Recipient : Stanford University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

                            Details : Fiasp (Insulin Aspart) is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Fiasp

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            June 13, 2018

                            Lead Product(s) : Insulin aspart

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Recipient : Stanford University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IBUTILIDE FUMARATE

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Recipient : Vivek Reddy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization

                            Details : Ibutilide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Atrial Fibrillation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 12, 2017

                            Lead Product(s) : IBUTILIDE FUMARATE

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Vivek Reddy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Development of Applications of PillCamâ„¢ Endoscopy and Patency Systems and Clinical Evaluation of Their P...

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 04, 2017

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth